fluorodeoxyglucose f18 has been researched along with acipimox in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (41.67) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fazio, F; Landoni, C; Lucignani, G; Monti, LD; Moresco, RM; Piatti, P; Pozza, G; Stefani, I | 1 |
| Bergman, J; Haaparanta, M; Härkönen, R; Hartiala, J; Knuuti, MJ; Mäki, M; Nuutila, P; Ruotsalainen, U; Teräs, M; Voipio-Pulkki, LM; Wegelius, U; Yki-Järvinen, H | 1 |
| Bax, JJ; Cornel, JH; Heine, RJ; van Lingen, A; Veening, MA; Visser, CA; Visser, FC | 1 |
| Bax, JJ; Cornel, JH; Fioretti, PM; Krenning, EP; Poldermans, D; Rambaldi, R; Valkema, R; van Lingen, A; Visser, FC | 1 |
| Baum, RP; Hertel, A; Hör, G; Schröder, O | 1 |
| Bax, JJ; Boersma, E; Kam, BL; Krenning, EP; Poldermans, D; Rambaldi, R; Reijs, AE; Rietveld, T; Roelandt, JR; Valkema, R | 1 |
| Bax, JJ; Bountioukos, MA; Elhendy, A; Krenning, EP; Poldermans, D; Roelandt, JR; Schinkel, AF; Valkema, R; van Domburg, RT; Vourvouri, EC | 1 |
| Arsos, G; de Haas, M; de Klerk, J; de Vrey, E; Weijs, L | 1 |
| Boutley, H; Fay, R; Karcher, G; Lacolley, P; Marie, PY; Maskali, F; Maureira, P; Person, C; Poussier, S; Régnault, V; Tran, N | 1 |
| Bousquenaud, M; Boutley, H; Devaux, Y; Karcher, G; Marie, PY; Maskali, F; Poussier, S; Wagner, DR | 1 |
| Andersen, KF; Divilov, V; Koziorowski, J; Lewis, JS; Pillarsetty, N | 1 |
| Boutley, H; Karcher, G; Lacolley, P; Lhuillier, M; Louis, H; Marie, PY; Maskali, F; Poussier, S; Thornton, SN | 1 |
1 review(s) available for fluorodeoxyglucose f18 and acipimox
| Article | Year |
|---|---|
FDG SPECT in the assessment of myocardial viability. Comparison with dobutamine echo.
Topics: Cardiotonic Agents; Deoxyglucose; Dobutamine; Echocardiography; Exercise Test; Fluorodeoxyglucose F18; Glucose; Humans; Hypolipidemic Agents; Myocardial Contraction; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Predictive Value of Tests; Pyrazines; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon | 1997 |
4 trial(s) available for fluorodeoxyglucose f18 and acipimox
| Article | Year |
|---|---|
Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients. Role of free fatty acid and insulin levels.
Topics: Adult; Biological Transport, Active; Deoxyglucose; Diabetes Mellitus, Type 1; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Male; Myocardium; Pyrazines; Somatostatin; Tomography, Emission-Computed | 1995 |
Combined hyperinsulinaemic glucose clamp and oral acipimox for optimizing metabolic conditions during 18F-fluorodeoxyglucose gated PET cardiac imaging: comparative results.
Topics: Administration, Oral; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fluorodeoxyglucose F18; Glucose Clamp Technique; Heart; Humans; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Male; Middle Aged; Pyrazines; Radiopharmaceuticals; Reproducibility of Results; Tomography, Emission-Computed | 1998 |
Feasibility and image quality of dual-isotope SPECT using 18F-FDG and (99m)Tc-tetrofosmin after acipimox administration.
Topics: Administration, Oral; Chronic Disease; Coronary Artery Disease; Echocardiography; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart; Humans; Male; Middle Aged; Organophosphorus Compounds; Organotechnetium Compounds; Pyrazines; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Ventricular Dysfunction, Left | 2003 |
Effect of diabetes mellitus on myocardial 18F-FDG SPECT using acipimox for the assessment of myocardial viability.
Topics: Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Feasibility Studies; Female; Fluorodeoxyglucose F18; Heart Ventricles; Humans; Male; Middle Aged; Pyrazines; Radionuclide Imaging; Radiopharmaceuticals; Ventricular Dysfunction, Left | 2003 |
7 other study(ies) available for fluorodeoxyglucose f18 and acipimox
| Article | Year |
|---|---|
Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative.
Topics: Adult; Aged; Coronary Angiography; Deoxyglucose; Diabetes Mellitus, Type 2; Echocardiography; Female; Fluorodeoxyglucose F18; Glucose; Glucose Clamp Technique; Heart; Humans; Male; Middle Aged; Myocardial Infarction; Myocardium; Nicotinic Acids; Pyrazines; Radionuclide Ventriculography; Tomography, Emission-Computed | 1994 |
Optimal metabolic conditions during fluorine-18 fluorodeoxyglucose imaging; a comparative study using different protocols.
Topics: Aged; Blood Glucose; Coronary Disease; Deoxyglucose; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glucose Clamp Technique; Glucose Tolerance Test; Heart; Humans; Hypolipidemic Agents; Male; Middle Aged; Pyrazines; Tomography, Emission-Computed, Single-Photon | 1997 |
Intense [18F]FDG tongue uptake in a case of acipimox-related angio-oedema during FDG-PET myocardial viability study.
Topics: Administration, Oral; Angioedema; Fluorodeoxyglucose F18; Humans; Hypolipidemic Agents; Kidney Neoplasms; Myocardium; Perfusion; Positron-Emission Tomography; Pyrazines; Tongue | 2007 |
ECG-triggered 18F-fluorodeoxyglucose positron emission tomography imaging of the rat heart is dramatically enhanced by acipimox.
Topics: Animals; Cardiac-Gated Imaging Techniques; Dose-Response Relationship, Drug; Electrocardiography; Fluorodeoxyglucose F18; Glucose; Heart; Male; Positron-Emission Tomography; Pyrazines; Rats; Rats, Wistar; Ventricular Function, Left | 2010 |
Acipimox-enhanced ¹⁸F-fluorodeoxyglucose positron emission tomography for characterizing and predicting early remodeling in the rat infarct model.
Topics: Animals; Diastole; Disease Models, Animal; Fluorodeoxyglucose F18; Hypolipidemic Agents; Male; Myocardial Infarction; Myocardium; Positron-Emission Tomography; Predictive Value of Tests; Pyrazines; Radiopharmaceuticals; Rats; Rats, Wistar; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2012 |
Antilipolytic drug boosts glucose metabolism in prostate cancer.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Fluorodeoxyglucose F18; Glucose; Humans; Hypolipidemic Agents; Male; Mice; Mice, Nude; Positron-Emission Tomography; Prostatic Neoplasms; Pyrazines; Tissue Distribution | 2013 |
Assessment of the early stage of cardiac remodeling of spontaneously hypertensive heart failure rats using the quantitative 3-dimensional analysis provided by acipimox-enhanced FDG-PET.
Topics: Animals; Arterial Pressure; Cardiac Catheterization; Disease Models, Animal; Fibrosis; Fluorodeoxyglucose F18; Heart Failure; Heart Ventricles; Hypertension; Imaging, Three-Dimensional; Lipid Metabolism; Male; Positron-Emission Tomography; Predictive Value of Tests; Pyrazines; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Stroke Volume; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |